Jarushka Naidoo, Full Professor at Royal College of Surgeons in Ireland, shared a post on LinkedIn:
“Thanks ESMO for the opportunity to discuss 3 of the lung oral abstracts in the proffered paper session:
- Phase III MARIPOSA OS (Asian subgroup): demonstrates similar OS benefit to full
population. *Future biomarker subsets may further inform practice (baseline ctDNA, ctDNA clearance, p53/RB1) - Phase II/III investigator initiated trial by Tata Memorial Centre: crizotinib+chemotherapy v crizotinib: stopped early for futility, and toxicity signal. *More is not always more
- Ph II Alveltamig in SCLC: a new trispecific DLL3 TCE: demonstrates cORRs in ~60% range with durable responses
*Next gen DLL3 targeting shows promise.
Well done to all authors, what a privilege to help synthesize the data.”
More posts from ESMO Asia 2025.
